吉林大学学报(医学版) ›› 2023, Vol. 49 ›› Issue (4): 1099-1106.doi: 10.13481/j.1671-587X.20230435
• 综述 • 上一篇
收稿日期:
2022-06-20
出版日期:
2023-07-28
发布日期:
2023-07-26
通讯作者:
刘晓秋
E-mail:liuxiaoq@jlu.edu.cn
作者简介:
卢蔷薇(1997-),女,河南省周口市人,在读硕士研究生,主要从事间质性肺疾病和肺癌临床方面的研究。
基金资助:
Received:
2022-06-20
Online:
2023-07-28
Published:
2023-07-26
摘要:
结节病是一种病因不明的多系统累及的肉芽肿性疾病, 好发于呼吸系统,如不及时治疗,约20%的患者最终可能会发展为肺纤维化,严重时并发呼吸衰竭,最终导致死亡。结节病发展为肺纤维化后严重影响患者的生活质量及生存期。因此,深入了解纤维化型肺结节病的发病机制具有重要的临床意义。纤维化型肺结节病的发生与遗传学有关联,基因多态性、转录水平的调控和表观遗传改变等对纤维化型肺结节病的进展有重要影响。促纤维化因素、信号转导过程和免疫机制也参与促进结节病发展为肺纤维化。此外,结节病相关的肺纤维化患者可同时并发肿瘤,2种疾病之间可能存在关联,结节病可能会增加肿瘤的发病风险。结节病的临床分期及分型不同,治疗方案也不同。现对纤维化型肺结节病的发病机制中基因遗传学机制、促纤维化因素、免疫学机制、与特发性肺纤维化(IPF)和肿瘤的相关性及治疗方面的新进展进行综述,以进一步提高临床医生对该病的认识。
中图分类号:
卢蔷薇,韩闪,刘晓秋. 纤维化型肺结节病的发病机制及其影响因素的研究进展[J]. 吉林大学学报(医学版), 2023, 49(4): 1099-1106.
1 | BONHAM C A, STREK M E, PATTERSON K C. From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis[J].Curr Opin Pulm Med,2016,22(5): 484-491. |
2 | KONIGSBERG I R, MAIER L A, YANG I V. Epigenetics and sarcoidosis[J]. Eur Respir Rev, 2021, 30(160): 210076. |
3 | COLLINS B F, MCCLELLAND R L, HO L A, et al. Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?[J]. Respir Med, 2018, 144S: S20-S27. |
4 | CHEN X P, ZHOU Z X, ZHANG Y, et al. NOD2/CARD15 gene polymorphisms and sarcoidosis susceptibility: review and meta-analysis[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2018, 35(2): 115-122. |
5 | LENG D, HUAN C J, XIE T, et al. Meta-analysis of genetic programs between idiopathic pulmonary fibrosis and sarcoidosis[J]. PLoS One, 2013, 8(8): e71059. |
6 | BHATTARAI G, LEE Y H, LEE N H, et al. C-myb mediates inflammatory reaction against oxidative stress in human breast cancer cell line, MCF-7[J]. Cell Biochem Funct, 2011, 29(8): 686-693. |
7 | STOCK C J, SATO H, FONSECA C, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis[J]. Thorax, 2013, 68(5): 436-441. |
8 | LIU Y, LI H, XIAO T, et al. Epigenetics in immune-mediated pulmonary diseases[J]. Clin Rev Allergy Immunol, 2013, 45(3): 314-330. |
9 | MAEDA T, GUAN J Z, HIGUCHI Y, et al. Aging-related alterations of subtelomeric methylation in sarcoidosis patients[J]. J Gerontol A Biol Sci Med Sci, 2009, 64(7): 752-760. |
10 | JENY F, BERNAUDIN J F, VALEYRE D, et al. Hypoxia promotes a mixed inflammatory-fibrotic macrophages phenotype in active sarcoidosis[J]. Front Immunol, 2021, 12: 719009. |
11 | BIENER L, KRUSE J, TULETA I, et al. Association of proangiogenic and profibrotic serum markers with lung function and quality of life in sarcoidosis[J]. PLoS One, 2021, 16(2): e0247197. |
12 | LARDOT Y S C. Depressed urokinase activity in bronchoalveolar lavage fluid from patients with sarcoidosis, silicosis or idiopathic pulmonary Rbrosis: relationship to disease severity[J]. Biomarkers,1999,4(5): 361-372. |
13 | KOTANI I, SATO A, HAYAKAWA H, et al. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis[J]. Thromb Res, 1995, 77(6): 493-504. |
14 | LAZAR M H, CHRISTENSEN P J, DU M, et al. Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin[J]. Am J Respir Cell Mol Biol, 2004, 31(6): 672-678. |
15 | ZIEGENHAGEN M W, ROTHE M E, ZISSEL G,et al.Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2002, 19(3): 185-190. |
16 | ZIEGENHAGEN M W, BENNER U K, ZISSEL G, et al. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers[J]. Am J Respir Crit Care Med, 1997,156(5): 1586-1592. |
17 | ZISSEL G, HOMOLKA J, SCHLAAK J, et al. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis[J]. Am J Respir Crit Care Med, 1996, 154(3 Pt 1): 713-719. |
18 | PIOTROWSKI W J, KISZAŁKIEWICZ J, PASTUSZAK-LEWANDOSKA D, et al. TGF-β and SMADs mRNA expression in pulmonary sarcoidosis[J]. Adv Exp Med Biol, 2015, 852: 59-69. |
19 | PIOTROWSKI W J, KISZAŁKIEWICZ J, GÓRSKI P,et al. Immunoexpression of TGF-β/Smad and VEGF-A proteins in serum and BAL fluid of sarcoidosis patients[J]. BMC Immunol, 2015, 16: 58. |
20 | KRAAIJVANGER R, JANSSEN BONÁS M, VORSELAARS A D M, et al. Biomarkers in the diagnosis and prognosis of sarcoidosis: current use and future prospects[J]. Front Immunol, 2020, 11: 1443. |
21 | BENNETT D, BARGAGLI E, BIANCHI N, et al. Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis[J]. Respir Physiol Neurobiol, 2020, 273: 103323. |
22 | D’ALESSANDRO M, VITA E D, BERGANTINI L, et al. Galactin-1, 3 and 9: potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases[J]. Respir Physiol Neurobiol, 2020, 282: 103546. |
23 | LIU D H, CUI W, CHEN Q, et al. Can circulating interleukin-18 differentiate between sarcoidosis and idiopathic pulmonary fibrosis?[J]. Scand J Clin Lab Invest, 2011, 71(7): 593-597. |
24 | CINETTO F, AGOSTINI C. Advances in understanding the immunopathology of sarcoidosis and implications on therapy[J]. Expert Rev Clin Immunol, 2016, 12(9): 973-988. |
25 | MOLLER D R, FORMAN J D, LIU M C, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis[J]. J Immunol, 1996, 156(12): 4952-4960. |
26 | EISENSTEIN E M, WILLIAMS C B. The Treg/Th17 cell balance: a new paradigm for autoimmunity[J]. Pediatr Res, 2009, 65(7): 26-31. |
27 | KOLAHIAN S, FERNANDEZ I E, EICKELBERG O, et al. Immune mechanisms in pulmonary fibrosis[J]. Am J Respir Cell Mol Biol, 2016, 55(3): 309-322. |
28 | CELADA L J, KROPSKI J A, HERAZO-MAYA J D, et al. PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production[J]. Sci Transl Med, 2018, 10(460): eaar8356. |
29 | DANIIL Z, KITSANTA P, KAPOTSIS G, et al. CD8+T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosis[J].Respir Res,2005,6(1): 81. |
30 | SHENDEROV K, COLLINS S L, POWELL J D,et al. Immune dysregulation as a driver of idiopathic pulmonary fibrosis[J]. J Clin Invest, 2021, 131(2): e143226. |
31 | GODA C, BALLI D, BLACK M, et al. Loss of FOXM1 in macrophages promotes pulmonary fibrosis by activating p38 MAPK signaling pathway[J]. PLoS Genet, 2020, 16(4): e1008692. |
32 | LIU G X, ZHAI H Q, ZHANG T, et al. New therapeutic strategies for IPF:based on the “phagocytosis- secretion-immunization” network regulation mechanism of pulmonary macrophages[J].Biomedecine Pharmacother, 2019, 118: 109230. |
33 | SUN L, LOUIE M C, VANNELLA K M, et al. New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis[J]. Am J Physiol Lung Cell Mol Physiol, 2011, 300(3): L341-L353. |
34 | PECHKOVSKY D V, PRASSE A, KOLLERT F,et al.Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction[J]. Clin Immunol, 2010, 137(1): 89-101. |
35 | CHENG P, LI S, CHEN H. Macrophages in lung injury, repair, and fibrosis[J]. Cells, 2021, 10(2): 436. |
36 | KAMPHUIS L S, VAN ZELM M C, LAM K H,et al. Perigranuloma localization and abnormal maturation of B cells: emerging key players in sarcoidosis?[J]. Am J Respir Crit Care Med, 2013, 187(4): 406-416. |
37 | BERGANTINI L, CAMELI P, D'ALESSANDRO M, et al. NK and NKT-like cells in granulomatous and fibrotic lung diseases[J]. Clin Exp Med, 2019, 19(4): 487-494. |
38 | SAKULA A. Bronchial carcinoma and sarcoidosis[J]. Br J Cancer, 1963, 17(2): 206-212. |
39 | VERLEDEN G M, DU BOIS R M, BOUROS D,et al. Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin[J]. Eur Respir J Suppl, 2001, 32: 17s-29s. |
40 | RADISKY D C, KENNY P A, BISSELL M J. Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT?[J]. J Cell Biochem, 2007, 101(4): 830-839. |
41 | JAMMAL T E, PAVIC M, GERFAUD-VALENTIN M,et al. Sarcoidosis and cancer: a complex relationship[J]. Front Med (Lausanne), 2020, 7: 594118. |
42 | MIMURA K, MOCHIZUKI Y, NAKAHARA Y,et al. A case of primary lung cancer with swollen mediastinal lymph nodes due to pre-existing sarcoidosis[J]. J Jpn Respir Soc, 2011, 49(3): 208-213. |
43 | MURAMATSU M, KURIYAMA M, TAKAHASHI K,et al. A case of resected squamous cell carcinoma of the lung complicated with sarcoidosis[J]. J Jpn Respir Soc, 2000, 38(9): 720-725. |
44 | JEUNE I L, GRIBBIN J, WEST J, et al. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK[J]. Respir Med, 2007, 101(12): 2534-2540. |
45 | YATIM N, MATEUS C, CHARLES P. Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission[J]. Rev Med Interne, 2018, 39(2): 130-133. |
46 | JAMES W E, JUDSON M A. Therapeutic strategies for pulmonary sarcoidosis[J]. Expert Rev Respir Med, 2020, 14(4): 391-403. |
47 | Statement on sarcoidosis. Joint statement of the American thoracic society (ATS), the European respiratory society (ERS) and the world association of sarcoidosis and other granulomatous disorders (WASOG) adopted by the ATS board of directors and by the ERS executive committee, February 1999[J]. Am J Respir Crit Care Med, 1999, 160(2): 736-755. |
48 | BELPERIO J A, SHAIKH F, ABTIN F G, et al. Diagnosis and treatment of pulmonary sarcoidosis[J]. JAMA, 2022, 327(9): 856. |
49 | GERKE A K. Treatment of sarcoidosis: a multidisciplinary approach[J]. Front Immunol, 2020, 11: 545413. |
50 | LE V, CROUSER E D. Potential immunotherapies for sarcoidosis[J]. Expert Opin Biol Ther, 2018, 18(4): 399-407. |
51 | WOLLIN L, MAILLET I, QUESNIAUX V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis[J]. J Pharmacol Exp Ther, 2014, 349(2): 209-220. |
52 | GHAZIPURA M, MAMMEN M J, HERMAN D D, et al. Nintedanib in progressive pulmonary fibrosis: a systematic review and meta-analysis[J]. Ann Am Thorac Soc, 2022, 19(6): 1040-1049. |
53 | WUYTS W A, PAPIRIS S, MANALI E, et al. The burden of progressive fibrosing interstitial lung disease: a DELPHI approach[J]. Adv Ther, 2020, 37(7): 3246-3264. |
54 | RICHELDI L, KOLB M, JOUNEAU S, et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis[J]. BMC Pulm Med, 2020, 20(1): 3. |
55 | WELLS A U, FLAHERTY K R, BROWN K K, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial[J]. Lancet Respir Med,2020,8(5): 453-460. |
56 | CONTE E, GILI E, FAGONE E, et al. Effect of pirfenidone on proliferation,TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts[J]. Eur J Pharm Sci, 2014, 58: 13-19. |
57 | KORSTEN P, STROHMAYER K, BAUGHMAN R P,et al. Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach[J]. Clin Pulm Med, 2016, 23(2): 67-75. |
58 | BRAUN N A, CELADA L J, HERAZO-MAYA J D, et al. Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity[J].Am J Respir Crit Care Med,2014,190(5): 560-571. |
59 | CELADA L J, ROTSINGER J E, YOUNG A, et al. Programmed death-1 inhibition of phosphatidylinositol 3-kinase/AKT/mechanistic target of rapamycin signaling impairs sarcoidosis CD4+ T cell proliferation[J]. Am J Respir Cell Mol Biol, 2017, 56(1): 74-82. |
60 | PAOLETTI L, WHELAN T P M. Lung transplantation for interstitial lung disease[J]. Curr Respir Care Rep, 2014, 3(3): 96-102. |
[1] | 刘蒙,黄晓东,韩峥,朱庆曦,谭洁,田霞. 钙黏蛋白17对结直肠癌细胞增殖和凋亡的影响及其PI3K/AKT/mTOR信号通路调节机制[J]. 吉林大学学报(医学版), 2023, 49(4): 1008-1017. |
[2] | 靳莉,张小红,胡朝阳,李凤芝,崔永亮,李杨,刘倩倩,乔艳俊. 槲皮素对人肺癌A549细胞移植瘤模型小鼠移植瘤生长和肺转移及细胞侵袭和迁移的影响及其机制[J]. 吉林大学学报(医学版), 2023, 49(4): 1018-1026. |
[3] | 李婧婧,热孜宛古丽·艾斯凯尔null,邢婉怡,邹颖刚. 单侧卵巢原发性去分化脂肪肉瘤1例报告及文献复习[J]. 吉林大学学报(医学版), 2023, 49(4): 1040-1045. |
[4] | 林喆,王泰栋,黄晓巍,马超,庄雪峰,王雨辰,林贺,郭骏骐,律广富. 防风野生品对大鼠类风湿性关节炎的改善作用及其机制[J]. 吉林大学学报(医学版), 2023, 49(3): 617-624. |
[5] | 张斯琦,孙美琪,李泽颢,刘丹丹,胡城,方芳,王国庆. 沉默CD147对前列腺癌LNCaP细胞糖酵解的影响[J]. 吉林大学学报(医学版), 2023, 49(3): 634-639. |
[6] | 闫圣玉,刘昌化,许志杰,丁雅婷,谢亚锋,张侨,刘菀莹. lncRNA PAX8-AS1对结直肠癌细胞增殖、凋亡和侵袭的作用及其机制[J]. 吉林大学学报(医学版), 2023, 49(3): 656-664. |
[7] | 赵玉哲,赵怡然,冯丽,高山,王霞,曹文庆,张静. 微创旋切术联合传统开放手术在乳腺多发肿瘤治疗中的应用[J]. 吉林大学学报(医学版), 2023, 49(3): 750-756. |
[8] | 李婧婧,热孜宛古丽·艾斯凯尔,李丹丹,邹颖刚. 不同治疗方案对卵巢恶性生殖细胞肿瘤患者生育能力影响的研究进展[J]. 吉林大学学报(医学版), 2023, 49(3): 816-822. |
[9] | 李锐,谭晓冬,胡耀元. 茯苓酸对人胰腺癌PANC-1细胞迁移、侵袭和上皮间质转化的抑制作用[J]. 吉林大学学报(医学版), 2023, 49(2): 315-323. |
[10] | 孙逸飞,李迪诺,王玉彬. 姜黄素通过下调PI3K/Akt/mTOR信号通路蛋白表达对胃癌MGC-803细胞增殖和侵袭的抑制作用[J]. 吉林大学学报(医学版), 2023, 49(2): 332-340. |
[11] | 岳金金,庞一心,张秀梅. 沉默信息调节因子2对大肠癌细胞有氧糖酵解和生长增殖的调控作用及其机制[J]. 吉林大学学报(医学版), 2023, 49(2): 385-394. |
[12] | 杨仁义,彭书旺,王永恒,董宇轩,段姗姗. 甲状腺癌铁死亡预后风险模型的构建及其潜在机制的生物信息学分析[J]. 吉林大学学报(医学版), 2023, 49(2): 402-413. |
[13] | 张德洪,郑明珠,李家秋,路中. 基于MSR1 mRNA和蛋白在泛癌组织中表达的生物信息学分析及其意义[J]. 吉林大学学报(医学版), 2023, 49(2): 425-439. |
[14] | 陈猛猛,陈俊宇,高燕,房正轩,赵淑华,郑晶莹,刘淑香. 膜穿孔蛋白E在上皮性卵巢癌组织中的表达水平及其临床意义[J]. 吉林大学学报(医学版), 2023, 49(2): 440-451. |
[15] | 王涵,张亚丽,全海薇,母润红,邹雨彤,夏薇. 急性髓系白血病患者血清外泌体中miR-92a-3p的表达及其意义[J]. 吉林大学学报(医学版), 2023, 49(2): 467-472. |
|